Keros Therapeutics (KROS) Tops Q2 EPS by 37c

Keros Therapeutics (NASDAQ: KROS) reported Q2 EPS of ($0.76), $0.37 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $18.17 million versus the consensus estimate of $4.21 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Reading (RDI) Tops Q2 EPS by 4c